Cardiomyocyte Kit

Familial, idiopathic and drug-induced cardiovascular diseases are leading causes of mortality worldwide. Therefore, it is of great importance to increase our understanding of underlying pathophysiology mechanisms in order to develop effective treatments. hiPSC-derived cardiomyocytes can be utilized for safety and efficacy drug screening, providing novel possibilities for pre-clinical assessment of compound effects.

Pluricyte Cardiomyocytes are fully functional hiPSC-derived ventricular-like cardiomyocytes obtained through a 2D differentiation system without any genetic purification/selection procedures. The cells cultured in a serum free, well-defined maturation-promoting medium. They offer a valuable cell model for cardiotoxicity testing, drug screening and target validation, as well as for metabolism studies and electrophysiology applications.

Product Description

Catalog number


Kit contents

1.5M viable, cryopreserved Pluricyte Cardiomyocyte cells

100 mL Pluricyte Cardiomyocyte Medium (Cat. #: PM-2100-100mL)


>70% based on cardiac Troponin T expression. High purity of ventricular cardiomyocytes based on high MLC2v expression and manual patch clamp


High degree of structural sarcomere organization

Assay window

1st contractions appear 24-48 hours post-thaw

Electrically coupled monolayer forms in 3-4 days post thaw

Stable beating monolayers observed 7-8 days post thaw (15-40 BPM)

Electrophysiology-based assays optimal between 8-12 days after plating

Single cell action potential

Low resting membrane potential (~-78 mV)

Fast upstroke velocity and robust action potential amplitude

Monolayer field potential

Well-pronounced and robust de- and repolarization peaks,
enabling easy detection of field potential durations and
facilitating MEA assay analysis for pro-arrhythmia drug liability assessment studies.

Recommended Storage

Cryopreserved cells: liquid nitrogen vapor phase

Pluricyte Cardiomyocyte Medium: -20°C, after opening 4°C

Product Data


Supporting documents